<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01122030</url>
  </required_header>
  <id_info>
    <org_study_id>1007V9214</org_study_id>
    <nct_id>NCT01122030</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety and Efficacy of S-297995 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety of single doses of oral
      naldemedine in adults physically dependent on opioids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single dose of naldemedine or matching placebo will be administered orally to each cohort
      of 12 participants (9 treatments, 3 placebos) in the morning of Day 15 under fasted
      conditions. The first cohort will receive a 0.1 mg dose. Cohorts will continue to be enrolled
      at the next higher dose level until the highest dose level (3 mg) has been achieved or until
      the study is discontinued due to adverse events or Clinical Opioid Withdrawal Score of &gt;8. A
      0.03 mg dose will also be tested. A 0.01 mg dose will be tested if 4 or more subjects
      experience 1 or more bowel movements within the 24 hour period post dose in the 0.03 mg
      dosing cohort.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 19, 2010</start_date>
  <completion_date type="Actual">March 22, 2011</completion_date>
  <primary_completion_date type="Actual">February 23, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>From the first dose of study drug on Day 15 up to Day 24.</time_frame>
    <description>Severity of adverse events (AEs) was graded according to the following definitions:
Mild: The subject experiences awareness of symptoms but these are easily tolerated or managed without specific treatment
Moderate: The subject experiences discomfort enough to cause interference with usual activity, and/or the condition requires specific treatment
Severe: The subject is incapacitated with inability to work or do usual activity, and/or the event requires significant treatment measures.
The relationship of the event to the study drug was determined by the investigator.
A serious adverse event (SAE) is defined as any AE occurring at any dose that resulted in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 24 Hours Post-dose in Number of Spontaneous Bowel Movements (SBMs) Per Day</measure>
    <time_frame>Baseline (Day 1 to Day 15) and Day 15 to 16 (0 to 24 hours post-dose)</time_frame>
    <description>Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. A spontaneous bowel movement was defined as a bowel movement where no laxative or enema was used in the 24 hours preceding the bowel movement.
Baseline was defined as the average number of SBMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 48 Hours Post-dose in the Number of SBMs Per Day</measure>
    <time_frame>Baseline (Day 1 to Day 15) and Day 15 to Day 17 (0 to 48 hours post-dose)</time_frame>
    <description>Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. A spontaneous bowel movement was defined as a bowel movement where no laxative or enema was used in the 24 hours preceding the bowel movement. Baseline was defined as the average number of SBMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15). Forty-eight hours post-dose was defined as the average number of SBMs per day from 0 to 48 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 24 Hours Post-dose in Number of Bowel Movements (BM) Per Day</measure>
    <time_frame>Baseline and 24 hours post-dose</time_frame>
    <description>Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. Baseline was defined as the average number of BMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 48 Hours Post-dose in Number of Bowel Movements Per Day</measure>
    <time_frame>Baseline and 48 hours post-dose</time_frame>
    <description>Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. Baseline was defined as the average number of BMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15). Forty-eight hours post-dose was defined as the average number of BMs per day from 0 to 48 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 24 Hours Post-dose in Number of Complete Spontaneous Bowel Movements (CSBMs) Per Day</measure>
    <time_frame>Baseline and 24 hours post-dose</time_frame>
    <description>Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. A complete spontaneous bowel movement was defined as a bowel movement where no laxative or enema was used and the bowel movement resulted in a sensation of complete evacuation (based on the question of &quot;having a feeling of complete emptying after the bowel movement&quot;).
Baseline was defined as the average number of CSBMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 48 Hours Post-dose in Number of Complete Spontaneous Bowel Movements (CSBMs) Per Day</measure>
    <time_frame>Baseline and 48 hours post-dose</time_frame>
    <description>Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. A complete spontaneous bowel movement was defined as a bowel movement where no laxative or enema was used and the bowel movement resulted in a sensation of complete evacuation (based on the question of &quot;having a feeling of complete emptying after the bowel movement&quot;).
Baseline was defined as the average number of CSBMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15). Forty-eight hours post-dose was defined as the average number of CSBMs per day from 0 to 48 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Spontaneous Bowel Movement</measure>
    <time_frame>From first dose on Day 15 through Day 17</time_frame>
    <description>The time to first SBM during the Study Drug Administration Period was summarized using Kaplan-Meier estimates. Each participant's first SBM was counted as an event and the time to first SBM after dosing was calculated from the date and time of first dosing until the date and time of first SBM. Participants who dropped out or were lost to follow-up before the first SBM were censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Bowel Movement</measure>
    <time_frame>From first dose on Day 15 through Day 17</time_frame>
    <description>The time to first BM during the Study Drug Administration Period was summarized using Kaplan-Meier estimates. Each participant's first BM was counted as an event and the time to first BM after dosing was calculated from the date and time of first dosing until the date and time of first BM. Participants who dropped out or were lost to follow-up before the first BM were censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Complete Spontaneous Bowel Movement</measure>
    <time_frame>From first dose on Day 15 through Day 17</time_frame>
    <description>The time to first CSBM during the Study Drug Administration Period was summarized using Kaplan-Meier estimates. Each participant's first CSBM was counted as an event and the time to first CSBM after dosing was calculated from the date and time of first dosing until the date and time of first CSBM. Participants who dropped out or were lost to follow-up before the first CSBM were censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Straining During Bowel Movements</measure>
    <time_frame>Baseline, 24 hours post-dose and 48 hours post-dose</time_frame>
    <description>Straining during BMs was graded using the following scale: 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.
Baseline was defined as the average straining score of all BMs prior to receiving study drug (Day 1 to Day 15). The straining score at 24 and 48 hours post-dose was calculated as the average straining score from all bowel movements from 0 to 24 and 0 to 48 hours post-dose, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 24 Hours Post-dose in Number of Complete Bowel Movements Per Day</measure>
    <time_frame>Baseline and 24 hours post-dose</time_frame>
    <description>A complete bowel movement (CBM) was defined as a bowel movement that resulted in a sensation of complete evacuation based on the question &quot;Did you have a feeling of complete emptying after the bowel movement?&quot; Baseline was defined as the average number of CBMs per day prior to receiving study drug (Day 1 to Day 15).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 48 Hours Post-dose in Number of Complete Bowel Movements Per Day</measure>
    <time_frame>Baseline and 48 hours post-dose</time_frame>
    <description>A complete bowel movement (CBM) was defined as a bowel movement that resulted in a sensation of complete evacuation based on the question &quot;Did you have a feeling of complete emptying after the bowel movement?&quot; Baseline was defined as the average number of CBMs per day prior to receiving study drug (Day 1 to 15). Forty-eight hours post-dose was calculated as the average number of CBMs per day from 0 to 48 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Abdominal Bloating</measure>
    <time_frame>Baseline, 24 hours post-dose and 48 hours post-dose</time_frame>
    <description>Participants were asked to rate their abdominal bloating for the past 24 hours using the following scale:
0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe. Baseline was defined as the average abdominal bloating score prior to receiving study drug (Day 1 to Day 15). Abdominal bloating at 24 hours and 48 hours post-dose was calculated as the mean score from 0 to 24 and 0 to 48 hours post-dose respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Abdominal Discomfort</measure>
    <time_frame>Baseline, 24 hours post-dose and 48 hours post-dose</time_frame>
    <description>Participants were asked to rate their abdominal discomfort for the past 24 hours using the following scale:
0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe. Baseline was defined as the average abdominal discomfort score prior to receiving study drug (Day 1 to Day 15). Abdominal discomfort at 24 hours and 48 hours post-dose was calculated as the mean score from 0 to 24 and 0 to 48 hours post-dose respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in BM Consistency</measure>
    <time_frame>Baseline, 24 hours post-dose and 48 hours post-dose</time_frame>
    <description>Consistency of BMs was measured using the Bristol Stool Scale, as follows:
1 = separate hard lumps like nuts; 2 = sausage shaped but lumpy; 3 = like a sausage, but with cracks on its surface; 4 = like a sausage or a snake, smooth and soft; 5 = soft blobs and with clear-cut edges; 6 = floppy pieces with ragged edges/mushy stool; 7 = watery, no solid pieces, entirely liquid.
Baseline was defined as the average consistency of BMs prior to receiving study drug (Day 1 to Day 15). BM consistency at 24 hours and 48 hours post-dose was calculated as the average scores from all bowel movements from 0 to 24 and 0 to 48 hours post-dose, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of False Start Bowel Movements Per Day</measure>
    <time_frame>Baseline, 24 hours post-dose and 48 hours post-dose</time_frame>
    <description>A false start was defined as any attempted, but unsuccessful bowel movement (no solid or liquid fecal material was excreted) based on the question &quot;In the past 24 hours, how many times did you try to have a bowel movement but were unsuccessful?&quot; Baseline was defined as the average number of false start BMs per day prior to receiving study drug (Day 1 to Day 15).
The number of false start BMs per day at 24 hours and 48 hours post-dose was calculated as is the average number of false start BMs per day from 0 to 24 and 0 to 48 hours post-dose, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Number of Bowel Movements With No Straining Per Day</measure>
    <time_frame>Baseline, 24 hours post-dose and 48 hours post-dose</time_frame>
    <description>Straining during BMs was graded using the following scale:
0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe. A BM without straining was defined as a BM with a straining score = 0.
Baseline was defined as the average number of BMs without straining per day prior to receiving study drug (Day 1 to Day 15). The number of BMs without straining per day at 24 hours and 48 hours post-dose was calculated as the average number of BMs with no straining per day from 0 to 24 hours and 0 to 48 hours post-dose, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Rescue Medications Used Per Day</measure>
    <time_frame>Baseline, 24 hours post-dose and 48 hours post-dose</time_frame>
    <description>Baseline was defined as the average number of rescue medications used per day prior to receiving study drug (Day 1 to Day 15). The number of rescue medications used per day at 24 hours and 48 hours post-dose was calculated as the average number of rescue medications used per day from 0 to 24 hours and 0 to 48 hours post-dose, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Opiate Withdrawal Scale (COWS) Score &gt; 8 at Any Time During the Study</measure>
    <time_frame>The COWS assessments were performed at Screening, on Day 14, Day 15 (pre-dose and 1, 2, 3, 4, 5, 6 and 8 hours post-dose, and at unscheduled times as signs or symptoms indicate), on Days 16 and 17, and on Day 24/End of Study.</time_frame>
    <description>The COWS assessment consisted of 11 questions which rated the severity of opiate withdrawal symptoms, including resting pulse rate, gastrointestinal upset, sweating, restlessness, pupil size, tremor, anxiety or irritability, bone or joint aches, gooseflesh skin, yawning, and runny nose or tearing. Each symptom was rated on a scale from 0 (not present) to 4 or 5 (most severe). The total score was calculated by summing the 11 individual scores and ranged from 0 (no withdrawal symptoms) to 48 (worst symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Webster Opiate Withdrawal Scale (WOWS) Score &gt; 8 at Any Time During the Study</measure>
    <time_frame>The WOWS assessment was performed at Screening, Day 14, Day 15 at pre-dose , and 24 and 48 hours post-dose and at the Follow-up/End of Study visit (Day 24).</time_frame>
    <description>The Webster Opiate Withdrawal Scale (WOWS) assessment consisted of 7 questions which rate the severity of opiate withdrawal symptoms, including sweating, sleep, bone or joint aches, runny nose or tearing, gastrointestinal upset, anxiety or irritability and gooseflesh skin. Each symptom was rated on a scale from 0 (not present/no issues) to 4 or 5 (severe). The total score was calculated by summing the 7 individual scores and ranged from 0 (no withdrawal symptoms) to 29 (worst symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Naldemedine and Metabolite Nor-S-297995</measure>
    <time_frame>Blood samples were collected predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose.</time_frame>
    <description>The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration of Naldemedine and Metabolite Nor-S-297995</measure>
    <time_frame>Blood samples were collected predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose.</time_frame>
    <description>The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration of Naldemedine and Metabolite Nor-S-297995</measure>
    <time_frame>Blood samples were collected predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose.</time_frame>
    <description>The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method. Area under the plasma concentration versus time curve from time zero to the last sampling time at which concentrations were at or above the limit of quantitation, calculated using the linear trapezoidal rule for increasing concentrations and the logarithmic rule for decreasing concentrations (Linear Up/ Log Down).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to Infinity for Naldemedine and Metabolite Nor-S-297995</measure>
    <time_frame>Blood samples were collected predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose.</time_frame>
    <description>The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method. Area under the plasma concentration versus time curve from time zero to infinity, calculated using the formula: AUC0-inf = AUC0-t + Ct/λZ where Ct was the last measurable concentration and λZ was the apparent terminal elimination rate constant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Elimination Half-life of Naldemedine and Metabolite Nor-S-297995</measure>
    <time_frame>Blood samples were collected predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose.</time_frame>
    <description>The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method. The apparent elimination half-life was calculated using the formula t1/2,z = (ln2)/λZ</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Opioid Induced Bowel Dysfunction</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this cohort 9 participants received one 0.1 mg naldemedine tablet and 3 participants received matching placebo administered on Day 15 under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this cohort 9 participants received a single dose of 0.3 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this cohort 9 participants received a single dose of 1 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this cohort 9 participants received a single dose of 3 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this cohort 9 participants received a single dose of 0.03 mg naldemedine oral solution and 3 participants received matching placebo oral solution administered on Day 15 under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this cohort 9 participants received a single dose of 0.01 mg naldemedine oral solution and 3 participants received matching placebo oral solution administered on Day 15 under fasted conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naldemedine</intervention_name>
    <description>Tablets or solution for oral administration</description>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>S-297995</other_name>
    <other_name>Symproic®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets or solution for oral administration</description>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Understand and sign an informed consent form

          -  Males will agree to use an approved double-barrier method of contraception from Day 1
             until 1 month after study completion

          -  Subject tests negative on urine drug test unless the subject has a prescription for
             the drug(s) that test positive

        Exclusion Criteria:

          -  Subjects under opioid therapy for cancer-related pain or for the management of drug
             addiction

          -  Fecal incontinence, irritable bowel syndrome, inflammatory bowel disease, or other
             active medical disorders associated with diarrhea, intermittent loose stools, or
             constipation

          -  Subjects who have participated in any other investigational drug study within 30 days
             prior to Day 1

          -  Prior exposure to S-297995
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <results_first_submitted>April 19, 2017</results_first_submitted>
  <results_first_submitted_qc>April 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 30, 2017</results_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic pain</keyword>
  <keyword>Opioid physical dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at a single study center in the United States.</recruitment_details>
      <pre_assignment_details>Participants were randomized to naldemedine or placebo, screened for 13 days (Days 1-13), and admitted to the clinic on Day 14 for pre-admission assessments. Six cohorts were sequentially enrolled from Cohort 1 (0.1 mg) to Cohort 2 (0.3 mg), Cohort 3 (1 mg), and Cohort 4 (3 mg), and subsequent de-escalation in Cohorts 5 (0.03 mg) and 6 (0.01 mg).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pooled Placebo</title>
          <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
        </group>
        <group group_id="P2">
          <title>Naldemedine 0.01 mg</title>
          <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
        </group>
        <group group_id="P3">
          <title>Naldemedine 0.03 mg</title>
          <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
        </group>
        <group group_id="P4">
          <title>Naldemedine 0.1 mg</title>
          <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
        </group>
        <group group_id="P5">
          <title>Naldemedine 0.3 mg</title>
          <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
        </group>
        <group group_id="P6">
          <title>Naldemedine 1 mg</title>
          <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
        </group>
        <group group_id="P7">
          <title>Naldemedine 3 mg</title>
          <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pooled Placebo</title>
          <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
        </group>
        <group group_id="B2">
          <title>Naldemedine 0.01 mg</title>
          <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
        </group>
        <group group_id="B3">
          <title>Naldemedine 0.03 mg</title>
          <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
        </group>
        <group group_id="B4">
          <title>Naldemedine 0.1 mg</title>
          <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
        </group>
        <group group_id="B5">
          <title>Naldemedine 0.3 mg</title>
          <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
        </group>
        <group group_id="B6">
          <title>Naldemedine 1 mg</title>
          <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
        </group>
        <group group_id="B7">
          <title>Naldemedine 3 mg</title>
          <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="9"/>
            <count group_id="B7" value="9"/>
            <count group_id="B8" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.7" spread="8.55"/>
                    <measurement group_id="B2" value="41.4" spread="12.99"/>
                    <measurement group_id="B3" value="45.2" spread="13.13"/>
                    <measurement group_id="B4" value="45.6" spread="6.02"/>
                    <measurement group_id="B5" value="39.7" spread="10.64"/>
                    <measurement group_id="B6" value="36.6" spread="10.19"/>
                    <measurement group_id="B7" value="44.8" spread="9.09"/>
                    <measurement group_id="B8" value="43.3" spread="10.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Severity of adverse events (AEs) was graded according to the following definitions:
Mild: The subject experiences awareness of symptoms but these are easily tolerated or managed without specific treatment
Moderate: The subject experiences discomfort enough to cause interference with usual activity, and/or the condition requires specific treatment
Severe: The subject is incapacitated with inability to work or do usual activity, and/or the event requires significant treatment measures.
The relationship of the event to the study drug was determined by the investigator.
A serious adverse event (SAE) is defined as any AE occurring at any dose that resulted in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect.</description>
        <time_frame>From the first dose of study drug on Day 15 up to Day 24.</time_frame>
        <population>All participants who received any amount of study drug (safety population).</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Severity of adverse events (AEs) was graded according to the following definitions:
Mild: The subject experiences awareness of symptoms but these are easily tolerated or managed without specific treatment
Moderate: The subject experiences discomfort enough to cause interference with usual activity, and/or the condition requires specific treatment
Severe: The subject is incapacitated with inability to work or do usual activity, and/or the event requires significant treatment measures.
The relationship of the event to the study drug was determined by the investigator.
A serious adverse event (SAE) is defined as any AE occurring at any dose that resulted in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect.</description>
          <population>All participants who received any amount of study drug (safety population).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse events leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 24 Hours Post-dose in Number of Spontaneous Bowel Movements (SBMs) Per Day</title>
        <description>Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. A spontaneous bowel movement was defined as a bowel movement where no laxative or enema was used in the 24 hours preceding the bowel movement.
Baseline was defined as the average number of SBMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15).</description>
        <time_frame>Baseline (Day 1 to Day 15) and Day 15 to 16 (0 to 24 hours post-dose)</time_frame>
        <population>All randomized participants who received study drug and had at least 1 post-dose efficacy assessment completed (intent-to-treat population). Last observation carried forward (LOCF) imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 24 Hours Post-dose in Number of Spontaneous Bowel Movements (SBMs) Per Day</title>
          <description>Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. A spontaneous bowel movement was defined as a bowel movement where no laxative or enema was used in the 24 hours preceding the bowel movement.
Baseline was defined as the average number of SBMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15).</description>
          <population>All randomized participants who received study drug and had at least 1 post-dose efficacy assessment completed (intent-to-treat population). Last observation carried forward (LOCF) imputation was used.</population>
          <units>spontaneous bowel movements / day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.13"/>
                    <measurement group_id="O2" value="0.20" spread="0.14"/>
                    <measurement group_id="O3" value="0.24" spread="0.09"/>
                    <measurement group_id="O4" value="0.13" spread="0.13"/>
                    <measurement group_id="O5" value="0.17" spread="0.12"/>
                    <measurement group_id="O6" value="0.13" spread="0.09"/>
                    <measurement group_id="O7" value="0.23" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.51"/>
                    <measurement group_id="O2" value="0.11" spread="0.33"/>
                    <measurement group_id="O3" value="0.67" spread="0.71"/>
                    <measurement group_id="O4" value="0.56" spread="0.73"/>
                    <measurement group_id="O5" value="2.00" spread="1.32"/>
                    <measurement group_id="O6" value="3.89" spread="3.06"/>
                    <measurement group_id="O7" value="5.00" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 24 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.48"/>
                    <measurement group_id="O2" value="-0.09" spread="0.41"/>
                    <measurement group_id="O3" value="0.42" spread="0.72"/>
                    <measurement group_id="O4" value="0.43" spread="0.68"/>
                    <measurement group_id="O5" value="1.83" spread="1.34"/>
                    <measurement group_id="O6" value="3.76" spread="3.06"/>
                    <measurement group_id="O7" value="4.77" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0767</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of SBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8727</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of SBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6373</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of SBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of SBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of SBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of SBMs as a covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 48 Hours Post-dose in the Number of SBMs Per Day</title>
        <description>Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. A spontaneous bowel movement was defined as a bowel movement where no laxative or enema was used in the 24 hours preceding the bowel movement. Baseline was defined as the average number of SBMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15). Forty-eight hours post-dose was defined as the average number of SBMs per day from 0 to 48 hours post-dose.</description>
        <time_frame>Baseline (Day 1 to Day 15) and Day 15 to Day 17 (0 to 48 hours post-dose)</time_frame>
        <population>Intent-to-treat population; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 48 Hours Post-dose in the Number of SBMs Per Day</title>
          <description>Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. A spontaneous bowel movement was defined as a bowel movement where no laxative or enema was used in the 24 hours preceding the bowel movement. Baseline was defined as the average number of SBMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15). Forty-eight hours post-dose was defined as the average number of SBMs per day from 0 to 48 hours post-dose.</description>
          <population>Intent-to-treat population; LOCF imputation was used</population>
          <units>Spontaneous bowel movements / day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.13"/>
                    <measurement group_id="O2" value="0.20" spread="0.14"/>
                    <measurement group_id="O3" value="0.24" spread="0.09"/>
                    <measurement group_id="O4" value="0.13" spread="0.13"/>
                    <measurement group_id="O5" value="0.17" spread="0.12"/>
                    <measurement group_id="O6" value="0.13" spread="0.09"/>
                    <measurement group_id="O7" value="0.23" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.33"/>
                    <measurement group_id="O2" value="0.44" spread="0.39"/>
                    <measurement group_id="O3" value="0.67" spread="0.61"/>
                    <measurement group_id="O4" value="0.39" spread="0.49"/>
                    <measurement group_id="O5" value="1.06" spread="0.68"/>
                    <measurement group_id="O6" value="2.28" spread="1.80"/>
                    <measurement group_id="O7" value="2.67" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 48 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.32"/>
                    <measurement group_id="O2" value="0.24" spread="0.39"/>
                    <measurement group_id="O3" value="0.42" spread="0.65"/>
                    <measurement group_id="O4" value="0.26" spread="0.45"/>
                    <measurement group_id="O5" value="0.88" spread="0.68"/>
                    <measurement group_id="O6" value="2.15" spread="1.81"/>
                    <measurement group_id="O7" value="2.44" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8982</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of SBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4946</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of SBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9301</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of SBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0047</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of SBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of SBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of SBMs as a covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 24 Hours Post-dose in Number of Bowel Movements (BM) Per Day</title>
        <description>Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. Baseline was defined as the average number of BMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15).</description>
        <time_frame>Baseline and 24 hours post-dose</time_frame>
        <population>Intent-to-treat; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 24 Hours Post-dose in Number of Bowel Movements (BM) Per Day</title>
          <description>Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. Baseline was defined as the average number of BMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15).</description>
          <population>Intent-to-treat; LOCF imputation was used</population>
          <units>bowel movements / day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.18"/>
                    <measurement group_id="O2" value="0.34" spread="0.10"/>
                    <measurement group_id="O3" value="0.41" spread="0.22"/>
                    <measurement group_id="O4" value="0.35" spread="0.17"/>
                    <measurement group_id="O5" value="0.33" spread="0.12"/>
                    <measurement group_id="O6" value="0.29" spread="0.09"/>
                    <measurement group_id="O7" value="0.38" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.62"/>
                    <measurement group_id="O2" value="0.11" spread="0.33"/>
                    <measurement group_id="O3" value="0.67" spread="0.71"/>
                    <measurement group_id="O4" value="0.56" spread="0.73"/>
                    <measurement group_id="O5" value="2.00" spread="1.32"/>
                    <measurement group_id="O6" value="3.89" spread="3.06"/>
                    <measurement group_id="O7" value="5.00" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 24 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.65"/>
                    <measurement group_id="O2" value="-0.23" spread="0.36"/>
                    <measurement group_id="O3" value="0.25" spread="0.75"/>
                    <measurement group_id="O4" value="0.21" spread="0.76"/>
                    <measurement group_id="O5" value="1.67" spread="1.35"/>
                    <measurement group_id="O6" value="3.60" spread="3.10"/>
                    <measurement group_id="O7" value="4.62" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1334</p_value>
            <method>ANCOVA</method>
            <method_desc>P-value is from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of BMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3320</p_value>
            <method>ANCOVA</method>
            <method_desc>P-value is from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of BMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9371</p_value>
            <method>ANCOVA</method>
            <method_desc>P-value is from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of BMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <method_desc>P-value is from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of BMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-value is from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of BMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-value is from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of BMs as a covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 48 Hours Post-dose in Number of Bowel Movements Per Day</title>
        <description>Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. Baseline was defined as the average number of BMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15). Forty-eight hours post-dose was defined as the average number of BMs per day from 0 to 48 hours post-dose.</description>
        <time_frame>Baseline and 48 hours post-dose</time_frame>
        <population>Intent-to-treat population; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 48 Hours Post-dose in Number of Bowel Movements Per Day</title>
          <description>Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. Baseline was defined as the average number of BMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15). Forty-eight hours post-dose was defined as the average number of BMs per day from 0 to 48 hours post-dose.</description>
          <population>Intent-to-treat population; LOCF imputation was used</population>
          <units>bowel movements / day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.18"/>
                    <measurement group_id="O2" value="0.34" spread="0.10"/>
                    <measurement group_id="O3" value="0.41" spread="0.22"/>
                    <measurement group_id="O4" value="0.35" spread="0.17"/>
                    <measurement group_id="O5" value="0.33" spread="0.12"/>
                    <measurement group_id="O6" value="0.29" spread="0.09"/>
                    <measurement group_id="O7" value="0.38" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.51"/>
                    <measurement group_id="O2" value="0.61" spread="0.49"/>
                    <measurement group_id="O3" value="0.72" spread="0.71"/>
                    <measurement group_id="O4" value="0.56" spread="0.46"/>
                    <measurement group_id="O5" value="1.06" spread="0.68"/>
                    <measurement group_id="O6" value="2.28" spread="1.80"/>
                    <measurement group_id="O7" value="2.67" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to 48 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.53"/>
                    <measurement group_id="O2" value="0.27" spread="0.51"/>
                    <measurement group_id="O3" value="0.31" spread="0.67"/>
                    <measurement group_id="O4" value="0.21" spread="0.52"/>
                    <measurement group_id="O5" value="0.72" spread="0.70"/>
                    <measurement group_id="O6" value="1.99" spread="1.82"/>
                    <measurement group_id="O7" value="2.29" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7978</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of BMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7143</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of BMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7531</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of BMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0283</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of BMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of BMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of BMs as a covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 24 Hours Post-dose in Number of Complete Spontaneous Bowel Movements (CSBMs) Per Day</title>
        <description>Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. A complete spontaneous bowel movement was defined as a bowel movement where no laxative or enema was used and the bowel movement resulted in a sensation of complete evacuation (based on the question of “having a feeling of complete emptying after the bowel movement”).
Baseline was defined as the average number of CSBMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15).</description>
        <time_frame>Baseline and 24 hours post-dose</time_frame>
        <population>Intent-to-treat population; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 24 Hours Post-dose in Number of Complete Spontaneous Bowel Movements (CSBMs) Per Day</title>
          <description>Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. A complete spontaneous bowel movement was defined as a bowel movement where no laxative or enema was used and the bowel movement resulted in a sensation of complete evacuation (based on the question of “having a feeling of complete emptying after the bowel movement”).
Baseline was defined as the average number of CSBMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15).</description>
          <population>Intent-to-treat population; LOCF imputation was used</population>
          <units>complete spontaneous bowel movements/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.06"/>
                    <measurement group_id="O2" value="0.07" spread="0.09"/>
                    <measurement group_id="O3" value="0.07" spread="0.08"/>
                    <measurement group_id="O4" value="0.06" spread="0.10"/>
                    <measurement group_id="O5" value="0.01" spread="0.03"/>
                    <measurement group_id="O6" value="0.03" spread="0.04"/>
                    <measurement group_id="O7" value="0.10" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.24"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.11" spread="0.33"/>
                    <measurement group_id="O4" value="0.22" spread="0.44"/>
                    <measurement group_id="O5" value="0.11" spread="0.33"/>
                    <measurement group_id="O6" value="2.44" spread="2.55"/>
                    <measurement group_id="O7" value="3.00" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 24 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.25"/>
                    <measurement group_id="O2" value="-0.07" spread="0.09"/>
                    <measurement group_id="O3" value="0.04" spread="0.29"/>
                    <measurement group_id="O4" value="0.16" spread="0.44"/>
                    <measurement group_id="O5" value="0.10" spread="0.34"/>
                    <measurement group_id="O6" value="2.42" spread="2.55"/>
                    <measurement group_id="O7" value="2.90" spread="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6269</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CSBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7456</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CSBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1968</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CSBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8708</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CSBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CSBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CSBMs as a covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 48 Hours Post-dose in Number of Complete Spontaneous Bowel Movements (CSBMs) Per Day</title>
        <description>Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. A complete spontaneous bowel movement was defined as a bowel movement where no laxative or enema was used and the bowel movement resulted in a sensation of complete evacuation (based on the question of “having a feeling of complete emptying after the bowel movement”).
Baseline was defined as the average number of CSBMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15). Forty-eight hours post-dose was defined as the average number of CSBMs per day from 0 to 48 hours post-dose.</description>
        <time_frame>Baseline and 48 hours post-dose</time_frame>
        <population>Intent-to-treat population; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 48 Hours Post-dose in Number of Complete Spontaneous Bowel Movements (CSBMs) Per Day</title>
          <description>Participants completed a bowel function assessment daily diary to record information about bowel movements and constipation. A complete spontaneous bowel movement was defined as a bowel movement where no laxative or enema was used and the bowel movement resulted in a sensation of complete evacuation (based on the question of “having a feeling of complete emptying after the bowel movement”).
Baseline was defined as the average number of CSBMs per day during the 2 weeks prior to receiving study drug (Day 1 to Day 15). Forty-eight hours post-dose was defined as the average number of CSBMs per day from 0 to 48 hours post-dose.</description>
          <population>Intent-to-treat population; LOCF imputation was used</population>
          <units>complete spontaneous bowel movements/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.06"/>
                    <measurement group_id="O2" value="0.07" spread="0.09"/>
                    <measurement group_id="O3" value="0.07" spread="0.08"/>
                    <measurement group_id="O4" value="0.06" spread="0.10"/>
                    <measurement group_id="O5" value="0.01" spread="0.03"/>
                    <measurement group_id="O6" value="0.03" spread="0.04"/>
                    <measurement group_id="O7" value="0.10" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.19"/>
                    <measurement group_id="O2" value="0.17" spread="0.25"/>
                    <measurement group_id="O3" value="0.17" spread="0.25"/>
                    <measurement group_id="O4" value="0.17" spread="0.35"/>
                    <measurement group_id="O5" value="0.06" spread="0.17"/>
                    <measurement group_id="O6" value="1.39" spread="1.34"/>
                    <measurement group_id="O7" value="1.61" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to 48 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.16"/>
                    <measurement group_id="O2" value="0.10" spread="0.18"/>
                    <measurement group_id="O3" value="0.10" spread="0.25"/>
                    <measurement group_id="O4" value="0.10" spread="0.34"/>
                    <measurement group_id="O5" value="0.04" spread="0.17"/>
                    <measurement group_id="O6" value="1.36" spread="1.34"/>
                    <measurement group_id="O7" value="1.51" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6131</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CSBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9293</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CSBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7990</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CSBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7674</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CSBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CSBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0018</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values are from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CSBMs as a covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Spontaneous Bowel Movement</title>
        <description>The time to first SBM during the Study Drug Administration Period was summarized using Kaplan-Meier estimates. Each participant’s first SBM was counted as an event and the time to first SBM after dosing was calculated from the date and time of first dosing until the date and time of first SBM. Participants who dropped out or were lost to follow-up before the first SBM were censored.</description>
        <time_frame>From first dose on Day 15 through Day 17</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Spontaneous Bowel Movement</title>
          <description>The time to first SBM during the Study Drug Administration Period was summarized using Kaplan-Meier estimates. Each participant’s first SBM was counted as an event and the time to first SBM after dosing was calculated from the date and time of first dosing until the date and time of first SBM. Participants who dropped out or were lost to follow-up before the first SBM were censored.</description>
          <population>Intent-to-treat population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" lower_limit="12.4">Could not be estimated due to the low number of events</measurement>
                    <measurement group_id="O2" value="37.0" lower_limit="25.8">Could not be estimated due to the low number of events</measurement>
                    <measurement group_id="O3" value="13.9" lower_limit="8.2">Could not be estimated due to the low number of events</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="3.3">Could not be estimated due to the low number of events</measurement>
                    <measurement group_id="O5" value="4.7" lower_limit="2.8" upper_limit="6.2"/>
                    <measurement group_id="O6" value="1.4" lower_limit="1.0" upper_limit="2.3"/>
                    <measurement group_id="O7" value="0.7" lower_limit="0.6" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7434</p_value>
            <method>Log Rank</method>
            <method_desc>P-values were obtained from the log-rank test stratified by Gender.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>3.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4449</p_value>
            <method>Log Rank</method>
            <method_desc>P-values were obtained from the log-rank test stratified by Gender.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>4.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8129</p_value>
            <method>Log Rank</method>
            <method_desc>P-values were obtained from the log-rank test stratified by Gender.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>2.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Log Rank</method>
            <method_desc>P-values were obtained from the log-rank test stratified by Gender.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>7.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.29</ci_lower_limit>
            <ci_upper_limit>24.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <method_desc>P-values were obtained from the log-rank test stratified by Gender.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>9.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.09</ci_lower_limit>
            <ci_upper_limit>31.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <method_desc>P-values were obtained from the log-rank test stratified by Gender.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>202272814.</param_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Hazard Ratio is infinite due to small range of observed times in 3 mg group that has no overlap with the Placebo group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Bowel Movement</title>
        <description>The time to first BM during the Study Drug Administration Period was summarized using Kaplan-Meier estimates. Each participant’s first BM was counted as an event and the time to first BM after dosing was calculated from the date and time of first dosing until the date and time of first BM. Participants who dropped out or were lost to follow-up before the first BM were censored.</description>
        <time_frame>From first dose on Day 15 through Day 17</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Bowel Movement</title>
          <description>The time to first BM during the Study Drug Administration Period was summarized using Kaplan-Meier estimates. Each participant’s first BM was counted as an event and the time to first BM after dosing was calculated from the date and time of first dosing until the date and time of first BM. Participants who dropped out or were lost to follow-up before the first BM were censored.</description>
          <population>Intent-to-treat population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" lower_limit="12.4">Could not be estimated due to the low number of events</measurement>
                    <measurement group_id="O2" value="28.4" lower_limit="25.8" upper_limit="43.0"/>
                    <measurement group_id="O3" value="13.9" lower_limit="8.2">Could not be estimated due to the low number of events</measurement>
                    <measurement group_id="O4" value="25.1" lower_limit="3.3" upper_limit="57.3"/>
                    <measurement group_id="O5" value="4.7" lower_limit="2.8" upper_limit="6.2"/>
                    <measurement group_id="O6" value="1.4" lower_limit="1.0" upper_limit="2.3"/>
                    <measurement group_id="O7" value="0.7" lower_limit="0.6" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4923</p_value>
            <method>Log Rank</method>
            <method_desc>P-values are from the log rank test stratified by gender.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>4.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5479</p_value>
            <method>Log Rank</method>
            <method_desc>P-values are from the log rank test stratified by gender.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>4.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5060</p_value>
            <method>Log Rank</method>
            <method_desc>P-values are from the log rank test stratified by gender.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>3.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Log Rank</method>
            <method_desc>P-values are from the log rank test stratified by gender.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>7.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.27</ci_lower_limit>
            <ci_upper_limit>23.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <method_desc>P-values are from the log rank test stratified by gender.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>9.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.00</ci_lower_limit>
            <ci_upper_limit>30.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <method_desc>P-values are from the log rank test stratified by gender.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>192233779</param_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Hazard Ratio is infinite due to small range of observed times in 3 mg group that has no overlap with the Placebo group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Complete Spontaneous Bowel Movement</title>
        <description>The time to first CSBM during the Study Drug Administration Period was summarized using Kaplan-Meier estimates. Each participant’s first CSBM was counted as an event and the time to first CSBM after dosing was calculated from the date and time of first dosing until the date and time of first CSBM. Participants who dropped out or were lost to follow-up before the first CSBM were censored.</description>
        <time_frame>From first dose on Day 15 through Day 17</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Complete Spontaneous Bowel Movement</title>
          <description>The time to first CSBM during the Study Drug Administration Period was summarized using Kaplan-Meier estimates. Each participant’s first CSBM was counted as an event and the time to first CSBM after dosing was calculated from the date and time of first dosing until the date and time of first CSBM. Participants who dropped out or were lost to follow-up before the first CSBM were censored.</description>
          <population>Intent-to-treat population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Could not be estimated due to the low number of events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="37.0">Could not be estimated due to the low number of events</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="37.7">Could not be estimated due to the low number of events</measurement>
                    <measurement group_id="O4" value="NA">Could not be estimated due to the low number of events</measurement>
                    <measurement group_id="O5" value="NA">Could not be estimated due to the low number of events</measurement>
                    <measurement group_id="O6" value="1.7" lower_limit="1.3" upper_limit="2.3"/>
                    <measurement group_id="O7" value="0.8" lower_limit="0.6" upper_limit="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1523</p_value>
            <method>Log Rank</method>
            <method_desc>P-values are from the log rank test stratified by gender.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>19.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0856</p_value>
            <method>Log Rank</method>
            <method_desc>P-values are from the log rank test stratified by gender.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>4.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>27.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5284</p_value>
            <method>Log Rank</method>
            <method_desc>P-values are from the log rank test stratified by gender.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>10.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8594</p_value>
            <method>Log Rank</method>
            <method_desc>P-values are from the log rank test stratified by gender.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>8.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <method_desc>P-values are from the log rank test stratified by gender.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>59.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.55</ci_lower_limit>
            <ci_upper_limit>537.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Log Rank</method>
            <method_desc>P-values are from the log rank test stratified by gender.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>10.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.30</ci_lower_limit>
            <ci_upper_limit>52.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Straining During Bowel Movements</title>
        <description>Straining during BMs was graded using the following scale: 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.
Baseline was defined as the average straining score of all BMs prior to receiving study drug (Day 1 to Day 15). The straining score at 24 and 48 hours post-dose was calculated as the average straining score from all bowel movements from 0 to 24 and 0 to 48 hours post-dose, respectively.</description>
        <time_frame>Baseline, 24 hours post-dose and 48 hours post-dose</time_frame>
        <population>Intent-to-treat population with available data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Straining During Bowel Movements</title>
          <description>Straining during BMs was graded using the following scale: 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.
Baseline was defined as the average straining score of all BMs prior to receiving study drug (Day 1 to Day 15). The straining score at 24 and 48 hours post-dose was calculated as the average straining score from all bowel movements from 0 to 24 and 0 to 48 hours post-dose, respectively.</description>
          <population>Intent-to-treat population with available data at each time point</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.71"/>
                    <measurement group_id="O2" value="2.0" spread="0.78"/>
                    <measurement group_id="O3" value="2.2" spread="0.68"/>
                    <measurement group_id="O4" value="1.9" spread="0.90"/>
                    <measurement group_id="O5" value="2.0" spread="1.08"/>
                    <measurement group_id="O6" value="2.5" spread="0.97"/>
                    <measurement group_id="O7" value="1.7" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 24 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.76"/>
                    <measurement group_id="O2" value="-0.8">Standard deviation cannot be calculated when n=1</measurement>
                    <measurement group_id="O3" value="-0.2" spread="0.88"/>
                    <measurement group_id="O4" value="-0.7" spread="0.43"/>
                    <measurement group_id="O5" value="-0.1" spread="0.89"/>
                    <measurement group_id="O6" value="-0.5" spread="1.37"/>
                    <measurement group_id="O7" value="-0.9" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 48 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.87"/>
                    <measurement group_id="O2" value="0.2" spread="0.74"/>
                    <measurement group_id="O3" value="0.4" spread="0.80"/>
                    <measurement group_id="O4" value="-0.6" spread="0.67"/>
                    <measurement group_id="O5" value="0.1">Standard deviation cannot be calculated when n=1</measurement>
                    <measurement group_id="O6" value="-0.4" spread="0.42"/>
                    <measurement group_id="O7" value="-1.4" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 24 Hours Post-dose in Number of Complete Bowel Movements Per Day</title>
        <description>A complete bowel movement (CBM) was defined as a bowel movement that resulted in a sensation of complete evacuation based on the question “Did you have a feeling of complete emptying after the bowel movement?” Baseline was defined as the average number of CBMs per day prior to receiving study drug (Day 1 to Day 15).</description>
        <time_frame>Baseline and 24 hours post-dose</time_frame>
        <population>Intent-to-treat population; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 24 Hours Post-dose in Number of Complete Bowel Movements Per Day</title>
          <description>A complete bowel movement (CBM) was defined as a bowel movement that resulted in a sensation of complete evacuation based on the question “Did you have a feeling of complete emptying after the bowel movement?” Baseline was defined as the average number of CBMs per day prior to receiving study drug (Day 1 to Day 15).</description>
          <population>Intent-to-treat population; LOCF imputation was used</population>
          <units>complete bowel movements / day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.16"/>
                    <measurement group_id="O2" value="0.13" spread="0.14"/>
                    <measurement group_id="O3" value="0.11" spread="0.09"/>
                    <measurement group_id="O4" value="0.14" spread="0.12"/>
                    <measurement group_id="O5" value="0.04" spread="0.06"/>
                    <measurement group_id="O6" value="0.12" spread="0.15"/>
                    <measurement group_id="O7" value="0.19" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.24"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.11" spread="0.33"/>
                    <measurement group_id="O4" value="0.22" spread="0.44"/>
                    <measurement group_id="O5" value="0.11" spread="0.33"/>
                    <measurement group_id="O6" value="2.44" spread="2.55"/>
                    <measurement group_id="O7" value="3.00" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to 24 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.20"/>
                    <measurement group_id="O2" value="-0.13" spread="0.14"/>
                    <measurement group_id="O3" value="0.01" spread="0.31"/>
                    <measurement group_id="O4" value="0.09" spread="0.45"/>
                    <measurement group_id="O5" value="0.07" spread="0.35"/>
                    <measurement group_id="O6" value="2.32" spread="2.61"/>
                    <measurement group_id="O7" value="2.81" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5054</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were obtained from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9688</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were obtained from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6963</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were obtained from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9599</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were obtained from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were obtained from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were obtained from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CBMs as a covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 48 Hours Post-dose in Number of Complete Bowel Movements Per Day</title>
        <description>A complete bowel movement (CBM) was defined as a bowel movement that resulted in a sensation of complete evacuation based on the question “Did you have a feeling of complete emptying after the bowel movement?” Baseline was defined as the average number of CBMs per day prior to receiving study drug (Day 1 to 15). Forty-eight hours post-dose was calculated as the average number of CBMs per day from 0 to 48 hours post-dose.</description>
        <time_frame>Baseline and 48 hours post-dose</time_frame>
        <population>Intent-to-treat population; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 48 Hours Post-dose in Number of Complete Bowel Movements Per Day</title>
          <description>A complete bowel movement (CBM) was defined as a bowel movement that resulted in a sensation of complete evacuation based on the question “Did you have a feeling of complete emptying after the bowel movement?” Baseline was defined as the average number of CBMs per day prior to receiving study drug (Day 1 to 15). Forty-eight hours post-dose was calculated as the average number of CBMs per day from 0 to 48 hours post-dose.</description>
          <population>Intent-to-treat population; LOCF imputation was used</population>
          <units>complete bowel movements / day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.16"/>
                    <measurement group_id="O2" value="0.13" spread="0.14"/>
                    <measurement group_id="O3" value="0.11" spread="0.09"/>
                    <measurement group_id="O4" value="0.14" spread="0.12"/>
                    <measurement group_id="O5" value="0.04" spread="0.06"/>
                    <measurement group_id="O6" value="0.12" spread="0.15"/>
                    <measurement group_id="O7" value="0.19" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.19"/>
                    <measurement group_id="O2" value="0.17" spread="0.25"/>
                    <measurement group_id="O3" value="0.17" spread="0.25"/>
                    <measurement group_id="O4" value="0.22" spread="0.36"/>
                    <measurement group_id="O5" value="0.06" spread="0.17"/>
                    <measurement group_id="O6" value="1.39" spread="1.34"/>
                    <measurement group_id="O7" value="1.61" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 48 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.17"/>
                    <measurement group_id="O2" value="0.04" spread="0.15"/>
                    <measurement group_id="O3" value="0.06" spread="0.28"/>
                    <measurement group_id="O4" value="0.09" spread="0.38"/>
                    <measurement group_id="O5" value="0.01" spread="0.19"/>
                    <measurement group_id="O6" value="1.27" spread="1.38"/>
                    <measurement group_id="O7" value="1.42" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3441</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were obtained from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7159</p_value>
            <p_value_desc>P-values were obtained from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CBMs as a covariate.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7342</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were obtained from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8714</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were obtained from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were obtained from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CBMs as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were obtained from a non-parametric rank ANCOVA model with effects for dose group and gender, and baseline number of CBMs as a covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Abdominal Bloating</title>
        <description>Participants were asked to rate their abdominal bloating for the past 24 hours using the following scale:
0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe. Baseline was defined as the average abdominal bloating score prior to receiving study drug (Day 1 to Day 15). Abdominal bloating at 24 hours and 48 hours post-dose was calculated as the mean score from 0 to 24 and 0 to 48 hours post-dose respectively.</description>
        <time_frame>Baseline, 24 hours post-dose and 48 hours post-dose</time_frame>
        <population>Intent-to-treat population with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Abdominal Bloating</title>
          <description>Participants were asked to rate their abdominal bloating for the past 24 hours using the following scale:
0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe. Baseline was defined as the average abdominal bloating score prior to receiving study drug (Day 1 to Day 15). Abdominal bloating at 24 hours and 48 hours post-dose was calculated as the mean score from 0 to 24 and 0 to 48 hours post-dose respectively.</description>
          <population>Intent-to-treat population with available data at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.65"/>
                    <measurement group_id="O2" value="1.4" spread="0.95"/>
                    <measurement group_id="O3" value="1.5" spread="0.69"/>
                    <measurement group_id="O4" value="1.7" spread="0.87"/>
                    <measurement group_id="O5" value="1.7" spread="0.66"/>
                    <measurement group_id="O6" value="2.5" spread="0.64"/>
                    <measurement group_id="O7" value="1.3" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 24 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.83"/>
                    <measurement group_id="O2" value="0.0">Cannot be calculated when n=1</measurement>
                    <measurement group_id="O3" value="0.2" spread="1.09"/>
                    <measurement group_id="O4" value="-0.2" spread="1.03"/>
                    <measurement group_id="O5" value="0.3" spread="0.69"/>
                    <measurement group_id="O6" value="-0.5" spread="0.91"/>
                    <measurement group_id="O7" value="0.7" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 48 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.54"/>
                    <measurement group_id="O2" value="0.1" spread="0.86"/>
                    <measurement group_id="O3" value="0.2" spread="1.17"/>
                    <measurement group_id="O4" value="0.1" spread="0.89"/>
                    <measurement group_id="O5" value="0.4">Cannot be calculated when n=1</measurement>
                    <measurement group_id="O6" value="-0.8" spread="0.5"/>
                    <measurement group_id="O7" value="-0.2" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Abdominal Discomfort</title>
        <description>Participants were asked to rate their abdominal discomfort for the past 24 hours using the following scale:
0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe. Baseline was defined as the average abdominal discomfort score prior to receiving study drug (Day 1 to Day 15). Abdominal discomfort at 24 hours and 48 hours post-dose was calculated as the mean score from 0 to 24 and 0 to 48 hours post-dose respectively.</description>
        <time_frame>Baseline, 24 hours post-dose and 48 hours post-dose</time_frame>
        <population>Intent-to-treat population with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Abdominal Discomfort</title>
          <description>Participants were asked to rate their abdominal discomfort for the past 24 hours using the following scale:
0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe. Baseline was defined as the average abdominal discomfort score prior to receiving study drug (Day 1 to Day 15). Abdominal discomfort at 24 hours and 48 hours post-dose was calculated as the mean score from 0 to 24 and 0 to 48 hours post-dose respectively.</description>
          <population>Intent-to-treat population with available data at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.63"/>
                    <measurement group_id="O2" value="1.5" spread="0.98"/>
                    <measurement group_id="O3" value="2.0" spread="0.75"/>
                    <measurement group_id="O4" value="2.0" spread="0.74"/>
                    <measurement group_id="O5" value="1.9" spread="0.81"/>
                    <measurement group_id="O6" value="2.6" spread="0.77"/>
                    <measurement group_id="O7" value="1.7" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 24 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.78"/>
                    <measurement group_id="O2" value="-0.8">Cannot be calculated when n=1</measurement>
                    <measurement group_id="O3" value="-0.5" spread="0.80"/>
                    <measurement group_id="O4" value="-0.7" spread="1.30"/>
                    <measurement group_id="O5" value="0.3" spread="0.60"/>
                    <measurement group_id="O6" value="-0.1" spread="0.96"/>
                    <measurement group_id="O7" value="1.3" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 48 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.67"/>
                    <measurement group_id="O2" value="-0.3" spread="1.00"/>
                    <measurement group_id="O3" value="-0.2" spread="1.00"/>
                    <measurement group_id="O4" value="-0.4" spread="0.44"/>
                    <measurement group_id="O5" value="1.1">Cannot be calculated when n=1</measurement>
                    <measurement group_id="O6" value="-1.1" spread="1.07"/>
                    <measurement group_id="O7" value="-0.1" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in BM Consistency</title>
        <description>Consistency of BMs was measured using the Bristol Stool Scale, as follows:
1 = separate hard lumps like nuts; 2 = sausage shaped but lumpy; 3 = like a sausage, but with cracks on its surface; 4 = like a sausage or a snake, smooth and soft; 5 = soft blobs and with clear-cut edges; 6 = floppy pieces with ragged edges/mushy stool; 7 = watery, no solid pieces, entirely liquid.
Baseline was defined as the average consistency of BMs prior to receiving study drug (Day 1 to Day 15). BM consistency at 24 hours and 48 hours post-dose was calculated as the average scores from all bowel movements from 0 to 24 and 0 to 48 hours post-dose, respectively.</description>
        <time_frame>Baseline, 24 hours post-dose and 48 hours post-dose</time_frame>
        <population>Intent-to-treat population with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in BM Consistency</title>
          <description>Consistency of BMs was measured using the Bristol Stool Scale, as follows:
1 = separate hard lumps like nuts; 2 = sausage shaped but lumpy; 3 = like a sausage, but with cracks on its surface; 4 = like a sausage or a snake, smooth and soft; 5 = soft blobs and with clear-cut edges; 6 = floppy pieces with ragged edges/mushy stool; 7 = watery, no solid pieces, entirely liquid.
Baseline was defined as the average consistency of BMs prior to receiving study drug (Day 1 to Day 15). BM consistency at 24 hours and 48 hours post-dose was calculated as the average scores from all bowel movements from 0 to 24 and 0 to 48 hours post-dose, respectively.</description>
          <population>Intent-to-treat population with available data at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.24"/>
                    <measurement group_id="O2" value="3.2" spread="1.13"/>
                    <measurement group_id="O3" value="2.2" spread="1.12"/>
                    <measurement group_id="O4" value="3.0" spread="1.71"/>
                    <measurement group_id="O5" value="3.2" spread="1.33"/>
                    <measurement group_id="O6" value="3.2" spread="2.06"/>
                    <measurement group_id="O7" value="2.2" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 24 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="1.09"/>
                    <measurement group_id="O2" value="-3.0">Cannot be calculated when n=1</measurement>
                    <measurement group_id="O3" value="-0.0" spread="0.24"/>
                    <measurement group_id="O4" value="-1.4" spread="1.56"/>
                    <measurement group_id="O5" value="1.5" spread="1.44"/>
                    <measurement group_id="O6" value="1.9" spread="3.27"/>
                    <measurement group_id="O7" value="4.1" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 48 hours post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.45"/>
                    <measurement group_id="O2" value="0.2" spread="2.45"/>
                    <measurement group_id="O3" value="-0.3" spread="1.43"/>
                    <measurement group_id="O4" value="-1.0" spread="2.00"/>
                    <measurement group_id="O5" value="0.6">Cannot be calculated when n=1</measurement>
                    <measurement group_id="O6" value="0.7" spread="3.66"/>
                    <measurement group_id="O7" value="2.5" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of False Start Bowel Movements Per Day</title>
        <description>A false start was defined as any attempted, but unsuccessful bowel movement (no solid or liquid fecal material was excreted) based on the question “In the past 24 hours, how many times did you try to have a bowel movement but were unsuccessful?&quot; Baseline was defined as the average number of false start BMs per day prior to receiving study drug (Day 1 to Day 15).
The number of false start BMs per day at 24 hours and 48 hours post-dose was calculated as is the average number of false start BMs per day from 0 to 24 and 0 to 48 hours post-dose, respectively.</description>
        <time_frame>Baseline, 24 hours post-dose and 48 hours post-dose</time_frame>
        <population>Intent-to-treat population; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of False Start Bowel Movements Per Day</title>
          <description>A false start was defined as any attempted, but unsuccessful bowel movement (no solid or liquid fecal material was excreted) based on the question “In the past 24 hours, how many times did you try to have a bowel movement but were unsuccessful?&quot; Baseline was defined as the average number of false start BMs per day prior to receiving study drug (Day 1 to Day 15).
The number of false start BMs per day at 24 hours and 48 hours post-dose was calculated as is the average number of false start BMs per day from 0 to 24 and 0 to 48 hours post-dose, respectively.</description>
          <population>Intent-to-treat population; LOCF imputation was used</population>
          <units>false start bowel movements / day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.86"/>
                    <measurement group_id="O2" value="0.67" spread="1.00"/>
                    <measurement group_id="O3" value="0.67" spread="1.12"/>
                    <measurement group_id="O4" value="0.22" spread="0.44"/>
                    <measurement group_id="O5" value="0.56" spread="1.01"/>
                    <measurement group_id="O6" value="0.00" spread="0.00"/>
                    <measurement group_id="O7" value="0.33" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 24 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.89"/>
                    <measurement group_id="O2" value="0.44" spread="1.33"/>
                    <measurement group_id="O3" value="-0.11" spread="1.17"/>
                    <measurement group_id="O4" value="0.00" spread="0.50"/>
                    <measurement group_id="O5" value="-0.11" spread="0.60"/>
                    <measurement group_id="O6" value="2.56" spread="3.81"/>
                    <measurement group_id="O7" value="0.78" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 48 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.69"/>
                    <measurement group_id="O2" value="0.28" spread="1.18"/>
                    <measurement group_id="O3" value="0.22" spread="1.48"/>
                    <measurement group_id="O4" value="0.00" spread="0.50"/>
                    <measurement group_id="O5" value="-0.06" spread="0.58"/>
                    <measurement group_id="O6" value="1.61" spread="2.42"/>
                    <measurement group_id="O7" value="0.44" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Number of Bowel Movements With No Straining Per Day</title>
        <description>Straining during BMs was graded using the following scale:
0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe. A BM without straining was defined as a BM with a straining score = 0.
Baseline was defined as the average number of BMs without straining per day prior to receiving study drug (Day 1 to Day 15). The number of BMs without straining per day at 24 hours and 48 hours post-dose was calculated as the average number of BMs with no straining per day from 0 to 24 hours and 0 to 48 hours post-dose, respectively.</description>
        <time_frame>Baseline, 24 hours post-dose and 48 hours post-dose</time_frame>
        <population>Intent-to-treat population; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Number of Bowel Movements With No Straining Per Day</title>
          <description>Straining during BMs was graded using the following scale:
0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe. A BM without straining was defined as a BM with a straining score = 0.
Baseline was defined as the average number of BMs without straining per day prior to receiving study drug (Day 1 to Day 15). The number of BMs without straining per day at 24 hours and 48 hours post-dose was calculated as the average number of BMs with no straining per day from 0 to 24 hours and 0 to 48 hours post-dose, respectively.</description>
          <population>Intent-to-treat population; LOCF imputation was used</population>
          <units>bowel movements with no straining / day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.07"/>
                    <measurement group_id="O2" value="0.09" spread="0.11"/>
                    <measurement group_id="O3" value="0.05" spread="0.09"/>
                    <measurement group_id="O4" value="0.03" spread="0.07"/>
                    <measurement group_id="O5" value="0.05" spread="0.07"/>
                    <measurement group_id="O6" value="0.03" spread="0.05"/>
                    <measurement group_id="O7" value="0.07" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 24 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.07"/>
                    <measurement group_id="O2" value="-0.09" spread="0.11"/>
                    <measurement group_id="O3" value="0.06" spread="0.36"/>
                    <measurement group_id="O4" value="-0.03" spread="0.07"/>
                    <measurement group_id="O5" value="0.28" spread="0.71"/>
                    <measurement group_id="O6" value="0.41" spread="0.74"/>
                    <measurement group_id="O7" value="3.37" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 48 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.14"/>
                    <measurement group_id="O2" value="-0.03" spread="0.13"/>
                    <measurement group_id="O3" value="0.01" spread="0.21"/>
                    <measurement group_id="O4" value="-0.03" spread="0.07"/>
                    <measurement group_id="O5" value="0.12" spread="0.36"/>
                    <measurement group_id="O6" value="0.19" spread="0.38"/>
                    <measurement group_id="O7" value="1.76" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Rescue Medications Used Per Day</title>
        <description>Baseline was defined as the average number of rescue medications used per day prior to receiving study drug (Day 1 to Day 15). The number of rescue medications used per day at 24 hours and 48 hours post-dose was calculated as the average number of rescue medications used per day from 0 to 24 hours and 0 to 48 hours post-dose, respectively.</description>
        <time_frame>Baseline, 24 hours post-dose and 48 hours post-dose</time_frame>
        <population>Intent-to-treat population; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Rescue Medications Used Per Day</title>
          <description>Baseline was defined as the average number of rescue medications used per day prior to receiving study drug (Day 1 to Day 15). The number of rescue medications used per day at 24 hours and 48 hours post-dose was calculated as the average number of rescue medications used per day from 0 to 24 hours and 0 to 48 hours post-dose, respectively.</description>
          <population>Intent-to-treat population; LOCF imputation was used</population>
          <units>rescue medications / day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.36"/>
                    <measurement group_id="O2" value="0.18" spread="0.21"/>
                    <measurement group_id="O3" value="0.36" spread="0.43"/>
                    <measurement group_id="O4" value="0.53" spread="0.68"/>
                    <measurement group_id="O5" value="0.52" spread="0.84"/>
                    <measurement group_id="O6" value="0.28" spread="0.36"/>
                    <measurement group_id="O7" value="0.20" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 24 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.70"/>
                    <measurement group_id="O2" value="-0.18" spread="0.21"/>
                    <measurement group_id="O3" value="-0.36" spread="0.43"/>
                    <measurement group_id="O4" value="0.02" spread="1.13"/>
                    <measurement group_id="O5" value="-0.52" spread="0.84"/>
                    <measurement group_id="O6" value="-0.28" spread="0.36"/>
                    <measurement group_id="O7" value="-0.20" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 48 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.51"/>
                    <measurement group_id="O2" value="-0.01" spread="0.36"/>
                    <measurement group_id="O3" value="-0.25" spread="0.37"/>
                    <measurement group_id="O4" value="0.08" spread="0.80"/>
                    <measurement group_id="O5" value="-0.52" spread="0.84"/>
                    <measurement group_id="O6" value="-0.23" spread="0.38"/>
                    <measurement group_id="O7" value="-0.20" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Opiate Withdrawal Scale (COWS) Score &gt; 8 at Any Time During the Study</title>
        <description>The COWS assessment consisted of 11 questions which rated the severity of opiate withdrawal symptoms, including resting pulse rate, gastrointestinal upset, sweating, restlessness, pupil size, tremor, anxiety or irritability, bone or joint aches, gooseflesh skin, yawning, and runny nose or tearing. Each symptom was rated on a scale from 0 (not present) to 4 or 5 (most severe). The total score was calculated by summing the 11 individual scores and ranged from 0 (no withdrawal symptoms) to 48 (worst symptoms).</description>
        <time_frame>The COWS assessments were performed at Screening, on Day 14, Day 15 (pre-dose and 1, 2, 3, 4, 5, 6 and 8 hours post-dose, and at unscheduled times as signs or symptoms indicate), on Days 16 and 17, and on Day 24/End of Study.</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Opiate Withdrawal Scale (COWS) Score &gt; 8 at Any Time During the Study</title>
          <description>The COWS assessment consisted of 11 questions which rated the severity of opiate withdrawal symptoms, including resting pulse rate, gastrointestinal upset, sweating, restlessness, pupil size, tremor, anxiety or irritability, bone or joint aches, gooseflesh skin, yawning, and runny nose or tearing. Each symptom was rated on a scale from 0 (not present) to 4 or 5 (most severe). The total score was calculated by summing the 11 individual scores and ranged from 0 (no withdrawal symptoms) to 48 (worst symptoms).</description>
          <population>Safety population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="18.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O6" value="11.1" lower_limit="0.3" upper_limit="48.2"/>
                    <measurement group_id="O7" value="66.7" lower_limit="29.9" upper_limit="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Webster Opiate Withdrawal Scale (WOWS) Score &gt; 8 at Any Time During the Study</title>
        <description>The Webster Opiate Withdrawal Scale (WOWS) assessment consisted of 7 questions which rate the severity of opiate withdrawal symptoms, including sweating, sleep, bone or joint aches, runny nose or tearing, gastrointestinal upset, anxiety or irritability and gooseflesh skin. Each symptom was rated on a scale from 0 (not present/no issues) to 4 or 5 (severe). The total score was calculated by summing the 7 individual scores and ranged from 0 (no withdrawal symptoms) to 29 (worst symptoms).</description>
        <time_frame>The WOWS assessment was performed at Screening, Day 14, Day 15 at pre-dose , and 24 and 48 hours post-dose and at the Follow-up/End of Study visit (Day 24).</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O7">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Webster Opiate Withdrawal Scale (WOWS) Score &gt; 8 at Any Time During the Study</title>
          <description>The Webster Opiate Withdrawal Scale (WOWS) assessment consisted of 7 questions which rate the severity of opiate withdrawal symptoms, including sweating, sleep, bone or joint aches, runny nose or tearing, gastrointestinal upset, anxiety or irritability and gooseflesh skin. Each symptom was rated on a scale from 0 (not present/no issues) to 4 or 5 (severe). The total score was calculated by summing the 7 individual scores and ranged from 0 (no withdrawal symptoms) to 29 (worst symptoms).</description>
          <population>Safety population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="18.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O5" value="11.1" lower_limit="0.3" upper_limit="48.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of Naldemedine and Metabolite Nor-S-297995</title>
        <description>The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method.</description>
        <time_frame>Blood samples were collected predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose.</time_frame>
        <population>The pharmacokinetic (PK) analysis population included all randomized participants who received study drug and had at least one post-dose PK assessment completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of Naldemedine and Metabolite Nor-S-297995</title>
          <description>The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method.</description>
          <population>The pharmacokinetic (PK) analysis population included all randomized participants who received study drug and had at least one post-dose PK assessment completed.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Naldemedine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0837" spread="29.6"/>
                    <measurement group_id="O2" value="0.290" spread="28.9"/>
                    <measurement group_id="O3" value="1.00" spread="28.4"/>
                    <measurement group_id="O4" value="3.12" spread="30.2"/>
                    <measurement group_id="O5" value="9.68" spread="31.3"/>
                    <measurement group_id="O6" value="30.9" spread="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nor-S-297995</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Nor-S-297995 could not be quantified</measurement>
                    <measurement group_id="O2" value="NA">Nor-S-297995 could not be quantified</measurement>
                    <measurement group_id="O3" value="0.0713" spread="31.8"/>
                    <measurement group_id="O4" value="0.134" spread="27.6"/>
                    <measurement group_id="O5" value="0.526" spread="49.4"/>
                    <measurement group_id="O6" value="1.50" spread="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Observed Plasma Concentration of Naldemedine and Metabolite Nor-S-297995</title>
        <description>The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method.</description>
        <time_frame>Blood samples were collected predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose.</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Plasma Concentration of Naldemedine and Metabolite Nor-S-297995</title>
          <description>The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method.</description>
          <population>PK population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Naldemedine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.5" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.5" upper_limit="4.0"/>
                    <measurement group_id="O3" value="2.5" lower_limit="0.5" upper_limit="5.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.72" upper_limit="3.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0.75" upper_limit="2.0"/>
                    <measurement group_id="O6" value="0.75" lower_limit="0.50" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nor-S-297995</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Nor-S-297995 could not be quantified</measurement>
                    <measurement group_id="O2" value="NA">Nor-S-297995 could not be quantified</measurement>
                    <measurement group_id="O3" value="5.0" lower_limit="2.5" upper_limit="12"/>
                    <measurement group_id="O4" value="4.1" lower_limit="3.0" upper_limit="8.0"/>
                    <measurement group_id="O5" value="8.0" lower_limit="4.0" upper_limit="12"/>
                    <measurement group_id="O6" value="5.0" lower_limit="3.0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration of Naldemedine and Metabolite Nor-S-297995</title>
        <description>The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method. Area under the plasma concentration versus time curve from time zero to the last sampling time at which concentrations were at or above the limit of quantitation, calculated using the linear trapezoidal rule for increasing concentrations and the logarithmic rule for decreasing concentrations (Linear Up/ Log Down).</description>
        <time_frame>Blood samples were collected predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose.</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration of Naldemedine and Metabolite Nor-S-297995</title>
          <description>The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method. Area under the plasma concentration versus time curve from time zero to the last sampling time at which concentrations were at or above the limit of quantitation, calculated using the linear trapezoidal rule for increasing concentrations and the logarithmic rule for decreasing concentrations (Linear Up/ Log Down).</description>
          <population>PK population</population>
          <units>ng*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Naldemedine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5863" spread="34.3"/>
                    <measurement group_id="O2" value="2.111" spread="31.4"/>
                    <measurement group_id="O3" value="11.71" spread="21.4"/>
                    <measurement group_id="O4" value="31.29" spread="30.5"/>
                    <measurement group_id="O5" value="93.60" spread="34.6"/>
                    <measurement group_id="O6" value="218.2" spread="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nor-S-297995</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Nor-S-297995 could not be quantified</measurement>
                    <measurement group_id="O2" value="NA">Nor-S-297995 could not be quantified</measurement>
                    <measurement group_id="O3" value="0.5856" spread="232.7"/>
                    <measurement group_id="O4" value="1.869" spread="68.3"/>
                    <measurement group_id="O5" value="14.97" spread="76.3"/>
                    <measurement group_id="O6" value="41.94" spread="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero to Infinity for Naldemedine and Metabolite Nor-S-297995</title>
        <description>The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method. Area under the plasma concentration versus time curve from time zero to infinity, calculated using the formula: AUC0-inf = AUC0-t + Ct/λZ where Ct was the last measurable concentration and λZ was the apparent terminal elimination rate constant.</description>
        <time_frame>Blood samples were collected predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose.</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero to Infinity for Naldemedine and Metabolite Nor-S-297995</title>
          <description>The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method. Area under the plasma concentration versus time curve from time zero to infinity, calculated using the formula: AUC0-inf = AUC0-t + Ct/λZ where Ct was the last measurable concentration and λZ was the apparent terminal elimination rate constant.</description>
          <population>PK population</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Naldemedine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8023" spread="33.8"/>
                    <measurement group_id="O2" value="2.294" spread="30.2"/>
                    <measurement group_id="O3" value="12.04" spread="21.7"/>
                    <measurement group_id="O4" value="31.87" spread="29.9"/>
                    <measurement group_id="O5" value="94.53" spread="34.8"/>
                    <measurement group_id="O6" value="219.9" spread="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nor-S-297995</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Nor-S-297995 could not be quantified</measurement>
                    <measurement group_id="O2" value="NA">Nor-S-297995 could not be quantified</measurement>
                    <measurement group_id="O3" value="3.046" spread="63.0"/>
                    <measurement group_id="O4" value="4.515" spread="58.8"/>
                    <measurement group_id="O5" value="17.10" spread="73.4"/>
                    <measurement group_id="O6" value="44.91" spread="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Elimination Half-life of Naldemedine and Metabolite Nor-S-297995</title>
        <description>The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method. The apparent elimination half-life was calculated using the formula t1/2,z = (ln2)/λZ</description>
        <time_frame>Blood samples were collected predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose.</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Naldemedine 0.01 mg</title>
            <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.03 mg</title>
            <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.3 mg</title>
            <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O5">
            <title>Naldemedine 1 mg</title>
            <description>Participants received a single dose of 1 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
          <group group_id="O6">
            <title>Naldemedine 3 mg</title>
            <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Elimination Half-life of Naldemedine and Metabolite Nor-S-297995</title>
          <description>The plasma concentration of naldemedine and its metabolite Nor-S-297995 were measured by liquid chromatography/tandem mass spectrometry (LC/MS/MS) method. The apparent elimination half-life was calculated using the formula t1/2,z = (ln2)/λZ</description>
          <population>PK population</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Naldemedine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.13" spread="58.3"/>
                    <measurement group_id="O2" value="7.46" spread="38.5"/>
                    <measurement group_id="O3" value="12.6" spread="35.6"/>
                    <measurement group_id="O4" value="12.2" spread="34.6"/>
                    <measurement group_id="O5" value="10.8" spread="20.9"/>
                    <measurement group_id="O6" value="11.6" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nor-S-297995</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Nor-S-297995 could not be quantified</measurement>
                    <measurement group_id="O2" value="NA">Nor-S-297995 could not be quantified</measurement>
                    <measurement group_id="O3" value="24.6" spread="52.7"/>
                    <measurement group_id="O4" value="25.7" spread="61.8"/>
                    <measurement group_id="O5" value="16.0" spread="24.8"/>
                    <measurement group_id="O6" value="17.0" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug on Day 15 up to Day 24 (10 days).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pooled Placebo</title>
          <description>Participants received a single dose of matching placebo administered orally on Day 15 under fasted conditions.</description>
        </group>
        <group group_id="E2">
          <title>Naldemedine 0.01 mg</title>
          <description>Participants received a single dose of 0.01 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
        </group>
        <group group_id="E3">
          <title>Naldemedine 0.03 mg</title>
          <description>Participants received a single dose of 0.03 mg naldemedine oral solution administered on Day 15 under fasted conditions.</description>
        </group>
        <group group_id="E4">
          <title>Naldemedine 0.1 mg</title>
          <description>Participants received one 0.1 mg naldemedine tablet administered on Day 15 under fasted conditions.</description>
        </group>
        <group group_id="E5">
          <title>Naldemedine 0.3 mg</title>
          <description>Participants received a single dose of 0.3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
        </group>
        <group group_id="E6">
          <title>Naldemedine 1 mg</title>
          <description>Participants received a single dose of 1mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
        </group>
        <group group_id="E7">
          <title>Naldemedine 3 mg</title>
          <description>Participants received a single dose of 3 mg naldemedine tablets administered on Day 15 under fasted conditions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Tongue discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Venipuncture site thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infusion site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood prolactin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shionogi Clinical Trials Administrator</name_or_title>
      <organization>Shionogi Inc.</organization>
      <phone>800-849-9707</phone>
      <email>shionogiclintrials-admin@shionogi.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

